NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

9480	Companies
185558	Keywords
117947	Articles
99388	Press releases

Home
Companies
NanoViricides, Inc.

BRIEF

published on 07/16/2025 at 14:35, 4 months 20 days ago

NanoViricides fait progresser le traitement MPox dans le cadre de la prolongation de l'autorisation d'urgence de l'OMS

NV-387 Essais Cliniques Épidémie De MPox Urgence De L'OMS Innovation Antivirale
BRIEF

published on 07/16/2025 at 14:35, 4 months 20 days ago

NanoViricides Advances MPox Treatment Amid WHO Emergency Extension

NV-387 Clinical Trials MPox Epidemic WHO Emergency Antiviral Innovation
PRESS RELEASE

published on 07/16/2025 at 14:30, 4 months 20 days ago

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides
NanoViricides, Inc. comments on WHO's extension of the MPox Public Health Emergency of International Concern and highlights the development of NV-387, a potential broad-spectrum antiviral for MPOX treatment

NanoViricides NV-387 Clinical Trial Mpox Antiviral
BRIEF

published on 07/14/2025 at 12:35, 4 months 22 days ago

NanoViricides Nears Completion of Adaptive Trial Design for MPox Drug NV-387

NanoViricides Clinical Trial Regulatory Approvals MPOX Treatment NV-387 Drug
BRIEF

published on 07/14/2025 at 12:35, 4 months 22 days ago

NanoViricides est sur le point d'achever la conception de l'essai adaptatif pour le médicament MPox NV-387

NanoViricides Essai Clinique Approbations Réglementaires Médicament NV-387 Traitement MPox
PRESS RELEASE

published on 07/14/2025 at 12:30, 4 months 22 days ago

Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides
NanoViricides, Inc. announces design completion of adaptive clinical trial protocol for MPox Virus treatment. Trial to evaluate dosing regimen, safety, and effectiveness in 80 patients

NV-387 Clinical Trial NanoViricides Inc. Antiviral Mpox Virus
BRIEF

published on 07/01/2025 at 12:35, 5 months 4 days ago

NanoViricides Advances NV-387 to Phase II for MPox Treatment

NV-387 Antiviral Drugs Phase II Trial MPOX Treatment Strategic Stockpile
BRIEF

published on 07/01/2025 at 12:35, 5 months 4 days ago

NanoViricides fait passer le NV-387 en phase II pour le traitement MPox

NV-387 Essai De Phase II Médicaments Antiviraux Traitement MPox Réserve Stratégique
PRESS RELEASE

published on 07/01/2025 at 12:30, 5 months 4 days ago

There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate
NanoViricides, Inc. announces advancing lead candidate NV-387 into Phase II clinical development for MPox. Protocol development and site addition underway in the DRC. Focus on antiviral drug against MPox/Smallpox

NV-387 NanoViricides Inc. Antiviral Drug Mpox Phase II
BRIEF

published on 06/18/2025 at 12:35, 5 months 17 days ago

NanoViricides Presents NV-387 as Leading Antiviral Defense

Pandemic Preparedness NV-387 Antiviral COVID Variants Bird Flu Threat Broad-spectrum Efficacy

Accesswire

Published on 12/05/2025 at 21:45, 20 minutes ago

When the Architecture Becomes Visible: The SMX Revaluation Explained
Published on 12/05/2025 at 21:30, 35 minutes ago

The Identity Layer Beneath Everything: Why Markets Are Revaluing SMX All at Once
Published on 12/05/2025 at 21:20, 45 minutes ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
Published on 12/05/2025 at 21:00, 1 hour 5 minutes ago

The Repricing Event: Why Multiple Global Industries Are Suddenly Moving Toward SMX
Published on 12/05/2025 at 20:25, 1 hour 40 minutes ago

The Feedback Loop: Why SMX's Adoption in One Industry Accelerates Interest in All the Others

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 18:58, 3 hours 7 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 3 hours 39 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 3 hours 50 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:51, 4 hours 14 minutes ago

Issue of Equity
Published on 12/05/2025 at 17:46, 4 hours 19 minutes ago

Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds

Les Echos

Published on 12/05/2025 at 17:18, 4 hours 47 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 4 hours 47 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 6 hours 55 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 6 hours 55 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 8 hours 7 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE

View all LES ECHOS COMFI WIRE